Has Ramsy Abdelghani, MD received payments from drug or device companies?

Yes. Drug and device makers reported $307,714 in general payments to Ramsy Abdelghani, MD across 345 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ramsy Abdelghani, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ramsy Abdelghani, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ramsy Abdelghani, MD

Pulmonary Disease · New Orleans, LANPI 1487997219

Payments from drug & device makers

What this record shows

This record is dominated by education: $231,347 of the $307,714 with a category attached, or 75.2%. Intuitive Surgical accounts for 94.4% of it on its own, with 25 other manufacturers making up the rest. Among pulmonary disease clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$307,714in general payments, 2019–2025

Across 345 payments — averaging $891.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Intuitive Surgical$290K
Boston Scientific$14K
Johnson & Johnson$1K
Pentax Of America, Inc.$500
Philips North America LLC$415
Pulmonx Corporation$415
plus $1K from 20 others

$166,654in research payments, 2019–2025

Across 12 payments — averaging $13,888 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Galvanize Therapeutics, Inc$167K

What the payments were for

Consulting fees$5000%
Speaking & faculty fees$30,10010%
Grants$12,5004%
Travel & lodging$17,7886%
Food & beverage$15,4235%
Education$231,34775%
Gifts$560%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Intuitive Surgical	279	$290,483
Boston Scientific	10	$13,648
Johnson & Johnson(3 entities)	6	$1,139
Pentax Of America, Inc.	1	$500
Philips North America LLC	9	$415
Pulmonx Corporation	9	$415
Galvanize Therapeutics, Inc	2	$221
Siemens Medical Solutions USA, Inc.	2	$116
Gilead	1	$87
ANI Pharmaceuticals, Inc.	1	$75
Olympus America Inc.	2	$69
Baxter Healthcare	2	$68
Pinnacle Biologics, Inc	1	$67
AbbVie	2	$48
Viatris Specialty LLC	2	$47
Regeneron Healthcare Solutions, Inc.	2	$46
Amgen	2	$43
Grifols USA, LLC	2	$42
Merck	2	$37
GSK	2	$33
Merz North America, Inc.	1	$30
United Therapeutics Corporation	1	$22
Boehringer Ingelheim	1	$18
AstraZeneca	1	$17
Sanofi	1	$15
Medtronic	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$307,714 in reported general payments places this provider in the 95th percentile of 189 pulmonary disease providers in Louisiana.

See all pulmonary disease providers in Louisiana →

Medicare billing

Part B allowed, 2024

$31,633

Medicare patients

Services billed

372

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in New Orleans

Joseph LaskyNew Orleans$447K
Juzar AliNew Orleans$216K
Nicole LapinelNew Orleans$140K
Courtney ShappleyNew Orleans$66K
Susan GunnNew Orleans$28K
David PattenNew Orleans$12K
Yasin KhanNew Orleans$12K
Ross KlingsbergNew Orleans$11K
Nereida ParadaNew Orleans$10K
Leonard GladeNew Orleans$10K

See the full list for Louisiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →